Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· March 31, 2026
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
View original at finance.yahoo.comAptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights Aptose Biosciences, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Shareholders have approved the proposed arrangement with Hanmi, which enables continued and expanded development of the TUS+VEN+AZA triplet
60% confidenceThe clinical trial data continue to support the promise of TUS+VEN+AZA therapy
60% confidenceTUS+VEN+AZA triplet has shown promising response rates and safety as a mutation agnostic therapy across a diverse population of patients newly diagnosed with AML
60% confidenceTUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations
60% confidence
Cited in these Via News reports
- AI-Designed Antibody BD200 Outperforms Standard Treatments in Drug-Resistant Cancers, Marking First Clinical Trial for Machine Learning Platform →
- Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy →
- Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals →
